Northwire Canada EditionSaturday, July 11, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Financings

PharmaCielo Announces Annual General Meeting and Intention to Issue Interest Shares

PCLO · Price

Executive Summary

  • PharmaCielo Ltd. announced its Annual General Meeting (AGM) will be held on April 2, 2026, with a record date of February 23, 2026.
  • The company intends to issue 12,153,937 “Interest Shares” at $0.08 per share to settle $972,317.12 of accrued semi‑annual interest on its 11% secured debentures, subject to TSX Venture Exchange approval.
  • The issuance price was calculated by dividing the cash interest payable by the number of shares issuable under each debenture, in accordance with applicable policies.

Key Details

  • AGM Information – Date: April 2, 2026; Record date for voting rights: February 23, 2026. Materials will be filed on SEDAR+.
  • Interest Shares Issuance – 12,153,937 common shares to be issued at an effective price of $0.08 per share.
  • Purpose of Issuance – To satisfy accrued semi‑annual interest payments totaling $972,317.12 on the Company’s 11% secured debentures.
  • Approval Required – Subject to approval by the TSX Venture Exchange and compliance with TSX Venture Exchange Policy 4.3, section 3.3.
  • Statutory Hold Period – The Interest Shares will be subject to any applicable statutory hold period under Canadian securities laws.
  • Contact for Further Information – Ian Atacan, Chief Financial Officer ([email protected]).

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Pharmacielo Ltd.